Sobi's commitment to delivering innovative treatment s for people living with hematological diseases is seen in global studies spanning multiple rare disorders, including myelofibrosis. A retrospective analysis will be presented that demonstrates the efficacy of pacritinib in spleen volume reduction, symptom benefit and red blood cell transfusion response, compared with best available therapy, in patients with myelofibrosis who have both thrombocytopenia and anemia. An additional retrospective analysis will be presented that shows the substantial symptom benefit pacritinib provides compared with best available therapy or low-dose ruxolitinib, specifically in patients who required red blood cell transfusion at the time of pacritinib initiation.
The number of patients experiencing treatment emergent Grade 3 anaemia was similar between pacritinib and BAT groups. New real-world data will be presented that demonstrates treatment with pacritinib provides stability or improvement in thrombocytopenia and/or anemia in patients with myelofibrosis, regardless of baseline counts, and has favorable overall survival similar to other JAK inhibitor historical controls. Key Sobi data to be presented at ASCO 2024 All abstracts can be accessed via the official ASCO website .
Contacts For details on how to contact the Sobi Investor Relations Team, please click here . For Sobi Media, click here . About Vonjo® VONJO is approved for the treatment of adults with intermediate- or high-risk primary o.
